A. The ATLAS Hesperidin trial of maintenance. Bevacizumab and erlotinib, the PASS-study chemotherapy first or second, and the beta version of bevacizumab to erlotinib in the second line setting of patients with brain metastases, with some receiving therapeutic anticoagulation central circulation treats nervous system in three patients ATLAS been reported in ATLAS and five patients and three patients in Passport Experienced pulmonary hemorrhage. These data show that patients treated with brain metastases, and patients receiving therapeutic anticoagulationmay treatedwith bevacizumab be. The h Ufigsten adverse events were h AVAiL in dermatological and GI-related, with a FREQUENCY Hnlichen H In all three treatment groups. Adverse events with an hour undAustreten Higher incidence of hypertension included bevacizumab, proteinuria.
H Moptyse was reported in 0.5% and 1.2% of patients Celecoxib Celebrex in the poor, low and high dose of bevacizumab and 1.3% of patients in the placebo arm. Serious lessons have been reported in 39%, 45% and 36% of patients. Although 9% of the study population was new U anticoagulant therapy was no pulmonary bleeding in the first process Results publication reported test or analysis of S Endh rte. Two large cohort studies focused on the e safety of bevacizumab. SAIL, which included 2.212 patients evaluated the safety of the first line of bevacizumab, 7.5 mg / kg and 15 mg / kg, in combination with chemotherapy. Zun Highest 4% of patients U seen again anticoagulation with bleeding in 924 patients.However, were major bleeding and H Moptysen rare and serious bleeding for some reason, it was reported in 81 patients.
Tive arterial and Sen thromboembolism occurred in 302 patients, and cerebral hemorrhage in seven patients. Heart failure was observed in 17 patients. Hypertension occurred in 790 patients, but only 125 patients had grade 3 hypertension. Proteinuria was reported in 764 patients, and gastrointestinal perforation have been reported in 30 patients. The ARIES study, which evaluated bevacizumab in combination with chemotherapy regimens in the first place, were patients with locally advanced or metastatic. The diagram on the line h Ufigsten used chemotherapy with bevacizumab was carboplatin / paclitaxel. Among the treated patients had brain metastases, 8% and 5% of the anticoagulant was obtained. A total of 45 patients had grade 3 bleeding, one had CNS bleeding, and 22 had severe arterial thromboembolic events.
Side effects in the total population Lkerung including normal grade 3 hypertension and bleeding. The results of the E4599 have an L Proposed Ngere OS in patients with hypertension and improved PFS with the development of high blood pressure w During bevacizumab treatment, although these results did not reach statistical significance. Similar results regarding the relationship between high blood pressure have been associated with bevacizumab and improved survival in the CALGB trial of 90 206 patients with metastatic renal cell carcinoma carcinoma.However, further investigation of this association is required has been reported. A recent Press Presentation of an extensive study of about 5,900 patients in six placebo-controlled POSE phase III trials of bevacizumab was hypertension Arisin